^
Association details:
| Biomarker: | KEAP1 deletion + KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC)
Published date:
08/08/2023
Excerpt:
We conducted a systematic search of randomized control clinical trials investigating IO, alone or with chemotherapy (CT), vs CT alone vs chemoimmunotherapy (CIT) in treatment-naïve advanced NSCLC patients...Our search resulted in 2140 publications and a total of 6658 patients with advanced NSCLC across 9 controlled clinical trials were included. We found that 7 trials demonstrated that patients with KRAS mutation and STK11 and /or KEAP11 loss responded poorly to PDL1 therapy. They have shorter DFS and/or OS.
